Edison has increased their valuation:
https://www.edisongroup.com/publication/novartis-licenses-ards-program/28353/Valuation: A$4.9bn or A$8.41 per share
We have increased our valuation to A$4.9bn or A$8.41 per share (A$7.88 per diluted share) from A$4.6bn or A$7.89 per share (A$7.53 per diluted share). The increase is mainly due to adding the ARDS program into our valuation now that it has been licensed by Novartis. We also rolled forward our NPV. These were offset in part by shifting Ryoncil approval to 2023, lowering the probability of success to 60% from 80% as well as lower net cash.
MSB Trading 2020 - a new dawn, page-11194
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |